Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.86 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12779371 | 0.90 | MAPK14 (0.83) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL4412457 | 0.90 | MAPK14 (1.00) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL12728790 | 0.89 | MAPK14 (0.89) | MAPK14MAPK11CYP3A4 | |
| Bms-582949 SCHEMBL254996 | 0.87 | MAPK14 (1.00) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL12729613 | 0.87 | MAPK14 (0.85) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL12729567 | 0.87 | MAPK14 (0.84) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL4408487 | 0.84 | MAPK14 (0.90) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL4112570 | 0.84 | MAPK14 (0.81) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL12729682 | 0.84 | MAPK14 (0.87) | MAPK14MAPK11CYP3A4 | |
| SCHEMBL12778998 | 0.83 | MAPK14 (1.00) | MAPK14MAPK11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098467-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20100240646-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| US-20100240646-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| US-7759343-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759343-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-23 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462616-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | MAPK14 219/4885MAPK11 255/4885CYP3A4 1917/4885 |
| US-20110098467-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | PLK2, CDK2, MAP3K15 | MAPK14 219/4885MAPK11 255/4885CYP3A4 1917/4885 |
| US-20090105243-A1 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors | PLK2, CDK2, MAP3K15 | MAPK14 219/4885MAPK11 255/4885CYP3A4 1917/4885 |
| US-20100240646-A1 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS | PLK2, CDK2, MAP3K15 | MAPK14 219/4885MAPK11 255/4885CYP3A4 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.